AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-588-1960
Debt
Current Ratio1.10
Quick Ratio1.10
Price-To-Earnings
Sales & Book Value
Annual Sales$7.58 million
Price / Sales32.41
Price / Cash FlowN/A
Price / Book-5.76
Profitability
Net Income$-65,020,000.00
Net Margins-590.02%
Return on Assets-54.94%
Miscellaneous
Employees19
OptionableOptionable
AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) posted its quarterly earnings results on Friday, November, 9th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. The biopharmaceutical company earned $2.47 million during the quarter, compared to analysts' expectations of $0.68 million. View AVEO Pharmaceuticals' Earnings History.
When is AVEO Pharmaceuticals' next earnings date?
What price target have analysts set for AVEO?
5 brokerages have issued 1 year price objectives for AVEO Pharmaceuticals' stock. Their predictions range from $3.00 to $9.00. On average, they anticipate AVEO Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 155.1% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.
What is the consensus analysts' recommendation for AVEO Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AVEO Pharmaceuticals.
What are Wall Street analysts saying about AVEO Pharmaceuticals stock?
Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We maintain our Buy rating on AVEO and our 12-month price target of $9.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.5% discount rate and 3% terminal growth rate. We derive an rNPV of $1.5B for the products and add in cash and cash equivalents of $18M to arrive at a 12-month price target of $9.16 per diluted share, which we round to $9.00." (1/14/2019)
- 2. According to Zacks Investment Research, "AVEO got a huge boost with the approval of Fotivda in Europe for first-line treatment of advanced renal cell carcinoma. AVEO is progressing well with its TIVO-3 study intended for an FDA nod in the United States. However, the company has extended the review timeline from the third to the fourth quarter of 2018 for top-line data from the phase III TIVO-3 study. Although, the targeted market is lucrative, dependence on partners for pipeline development as well as funds is a concern. Failure to receive regulatory approvals or the termination of a deal would hamper AVEO’s future prospects. AVEO suffered a string of pipeline setbacks in the past, which might leave an adverse impact on the stock. Moreover, shares of the company have underperformed the industry so far this year. Loss estimates have narrowed ahead of the company’s Q3 earnings release. The company has a dismal record of earnings surprises in recent quarters." (11/12/2018)
Has AVEO Pharmaceuticals been receiving favorable news coverage?
Media coverage about AVEO stock has been trending positive this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the stock's share price in the near term.
Are investors shorting AVEO Pharmaceuticals?
AVEO Pharmaceuticals saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 16,063,929 shares, a drop of 11.7% from the December 14th total of 18,194,882 shares. Based on an average trading volume of 1,874,564 shares, the days-to-cover ratio is presently 8.6 days. Currently, 16.1% of the shares of the stock are short sold. View AVEO Pharmaceuticals' Current Options Chain.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include Retrophin (RTRX), Tricida (TCDA), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN), Alder Biopharmaceuticals (ALDR), Epizyme (EPZM), AC Immune (ACIU), Y-mAbs Therapeutics (YMAB), Athenex (ATNX) and CytomX Therapeutics (CTMX).
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
- Mr. Matthew D. Dallas, Chief Financial Officer (Age 44)
- Dr. Michael N. Needle, Chief Medical Officer (Age 59)
- Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
- Dr. Emile Farhan Ph.D., VP of Technical Operations
Who are AVEO Pharmaceuticals' major shareholders?
AVEO Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.05%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.
Which major investors are buying AVEO Pharmaceuticals stock?
AVEO stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.
How do I buy shares of AVEO Pharmaceuticals?
Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO stock can currently be purchased for approximately $1.96.
How big of a company is AVEO Pharmaceuticals?
AVEO Pharmaceuticals has a market capitalization of $249.44 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.
What is AVEO Pharmaceuticals' official website?
How can I contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]
MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
